HITI Q3 FY2026 Research Packet

HOLDConviction 3 / 5Uncertainty: Very High

Fair value (base)$2.60range $1.14–$4.22

Price, Sep 14 regular close, USD$2.63-1% to base

Probability-weighted$2.49-5% expected

HOLD, with USD2.60 fair value. Germany is adding real operating profit, yet the headline net-income jump is dominated by valuation marks. The model values only High Tide’s economic ownership and charges for rent, financing and dilution risk. At USD2.63 there is little margin of safety, even while assuming better cash generation than the trailing record. Financial amounts are CAD; Nasdaq prices and fair values are USD.

▶ Watch the episode 🎧 Podcast

Layer 1 · fast

The 60-second read

RevenueC$198.8M32.8% YoY; acquired Germany is the main growth source

Operating incomeC$8.71M133% growth, separately from derivative gains

Reported net incomeC$12.75MC$10.50 M net fair-value benefit included

Adjusted net incomeC$2.25MCompany measure; consolidated, before minority allocation

Company FCFC$7.02M-8.7% YoY; sustaining capex and leases already deducted

Full-capex cash proxyC$5.61MComputed Q3 OCF less PPE, intangibles and lease payments

Unrestricted cashC$38.02MC$9.10 M restricted cash excluded from value offset

Remexian ownership51%Consolidated results include 100%; economic value does not

Five things to know

Germany now drives most incremental revenue. Remexian contributes C$38.23 M of the C$49.13 M year-on-year sales increase; legacy bricks-and-mortar segment revenue rises 7.3%.
Operating improvement survives the accounting clean-up. C$8.71 M operating income is up 133%, but the C$12.75 M net-income headline includes a C$11.79 M derivative gain offset by a C$1.29 M contract-asset loss.
Cash is positive, with a narrower definition than total reinvestment. C$7.02 M company FCF deducts sustaining capital and leases; replacing sustaining capital with all PPE and intangible purchases leaves C$5.61 M.
The balance-sheet and ownership bridge matters. Restricted cash, cash-settled financing, nonrecourse factoring and Remexian’s 49% minority share all affect the interpretation of consolidated results.
Price already requires continued progress. Three valuation routes span roughly USD2.39–2.74. The USD2.60 base case assumes stronger recurring owner cash flow, while current controls remain ineffective.

Layer 1 · the call

Three scenarios, one probability-weighted number

Analyst scenarios in USD per common share, not company guidance or price predictions.

Scenario values versus the quoted price · Computed from the disclosed model below; probabilities are judgment.

Show the data

Measure	Value
Bear	1.14
Base	2.6
Bull	4.22
Weighted	2.486
Sep 14 close	2.63

Scenario	Probability	12-month value	vs $2.63	What has to happen	The arithmetic
Bear	30%	$1.14	−57%	German momentum fades; domestic growth consumes cash; multiples contract.	(C$30 M owned after-rent/SBC profit × 6 − C$39.06 M net face debt) ÷ 88.897 M shares × 0.71948 USD/CAD = USD1.14.
Base	50%	$2.60	−1%	Current operating momentum persists, cash conversion improves, and no unfunded US expansion is credited.	Equal-weight three-route mean of USD2.743, USD2.705 and USD2.395 = USD2.614, rounded to USD2.60.
Bull	20%	$4.22	+60%	Germany sustains scale, Canada earns more from membership and stores, and owned cash profit rises.	(C$56 M owned after-rent/SBC profit × 10 − C$39.06 M net face debt) ÷ 88.897 M shares × 0.71948 = USD4.22.
Probability-weighted value: 30% × USD1.14 + 50% × USD2.60 + 20% × USD4.22 = USD2.486. The spread is large because regulatory, financial-control and reinvestment risks are substantial. Prices are rounded; this is not a statistical confidence interval.

Layer 1 · falsifiable

Signposts: what would change our mind

Signpost	Now (Q3 FY2026)	Green if	Red if	Next check
Owned recurring cash	Q3 full-capex proxy C$5.61 M, before NCI	Above C$6 M with stable working capital	Below C$3 M	Next FY2026 results; date unannounced, review by Jan 31 2027
German profitability	Q3 segment EBITDA C$4.41 M	At least C$4 M for next quarter	Below C$2 M	FY2026 results, review Jan 31 2027
Legacy segment growth	Bricks revenue +7.3% YoY	At least 5%, with positive operating income	Below 0%	FY2026 results, review Jan 31 2027
Canadian stores	229 at quarter end;232 at release	At least 20 calendar 2026 openings, returns maintained	Growth funded by material discounted equity	Dec 31 2026 operating update
Factoring discipline	C$19.13 M sold receivable offset	No acceleration beyond revenue growth	Factoring increases while underlying collections weaken	FY2026 statements, review Jan 31 2027
Controls	Ineffective; IT and complex transactions	Documented remediation operating effectively	Further material errors or weakness expansion	FY2026 annual report, review Jan 31 2027
Margin of safety	USD2.63 versus USD2.60 fair value	Price at/below USD1.82 with thesis intact	New debt, dilution or regulation cuts fair value	Review each reported quarter; Jan 31 2027 latest

Green and red conditions are analytical thresholds, not management forecasts. The next packet must grade these rows against reported evidence. A cheaper price alone cannot rescue a deteriorating thesis.

The tape

The regular close is a reference price, not a completed post-release reaction.

High Tide’s Nasdaq common share closed at USD2.63 on September 14. That price is up 3.95% from the preceding regular close, but it is not evidence of the market’s full reaction to this earnings release. The detailed interim filing reached EDGAR shortly before the close and the results release was accepted later. We therefore use the price solely as a dated valuation reference. The company’s call is scheduled for September 15 at 11:30 a.m. Eastern, after this research cutoff. No call commentary has been inferred, and the absence of a completed post-release session does not prevent analysis of the verified financial statements.

The stock is a small-cap cannabis retailer and distributor, with substantial regulatory and financing sensitivity. The source quote gives a USD2.02–4.055 fifty-two-week range and beta 1.038. Those historical descriptors are not downside limits. More importantly, FMP’s quoted market capitalization uses an older share denominator than the July financial statements. Multiplying the actual 88.897395 million common shares by USD2.63 gives approximatelyUSD233.80 million, rather than silently adopting the vendor’sUSD231.10 million. The float field also cites an older filing. A real valuation must keep the dated share count separate from the weighted average used to calculate quarterly earnings per share.The model uses the FMP CAD/USD quote of 0.71948 at September 15, 2026, 08:13:30 UTC (3:13:30 AM CDT). This FX observation is later than the September 14 regular-close stock reference; the model does not claim synchronized closing marks. All statement history remains in its disclosed Canadian-dollar currency.

Nasdaq referenceUSD2.63

Reference sessionSep 14 regular close

52-week lowUSD2.02

52-week highUSD4.055

Beta1.038

Current common shares88.897M

Q3 weighted basic87.934M

Q3 weighted diluted94.560M

Computed equity valueUSD233.80M

Price currencyUSD

Statements currencyCAD

FX referenceUSD0.71948/CAD

Fiscal year-endOctober 31

Quarter-end stores229

Release-date stores232

CallSep 15, pending at cutoff

Fifteen months of price against the valuation anchor · FMP daily unadjusted close in USD; fair-value line is today’s model, not historical forecasts.

Show the data

Date	USD close
2025-06-16	2.22
2025-07-17	2.5
2025-08-15	2.66
2025-09-16	3.71
2025-10-15	3.56
2025-11-13	2.87
2025-12-15	2.73
2026-01-15	2.51
2026-02-17	2.37
2026-03-18	2.45
2026-04-17	2.43
2026-05-18	2.34
2026-06-17	2.37
2026-07-20	2.16
2026-08-18	2.4

Quarter	Financial filing date	Next session	Reference close USD	Next close USD	Change %
2024 Q3	2024-09-16	2024-09-17	2.19	2.14	−2.28
2024 Q4	2025-01-30	2025-01-31	2.72	2.79	2.57
2025 Q1	2025-03-17	2025-03-18	2.43	2.07	−14.81
2025 Q2	2025-06-16	2025-06-17	2.22	2.25	1.35
2025 Q3	2025-09-15	2025-09-16	3.68	3.71	0.82
2025 Q4	2026-01-29	2026-01-30	2.43	2.23	−8.23
2026 Q1	2026-03-17	2026-03-18	2.49	2.45	−1.61
2026 Q2	2026-06-15	2026-06-16	2.25	2.52	12.0
2026 Q3	2026-09-14	Not complete	2.63	Unavailable	Unavailable
Next regular close versus filing-date close, based on SEC financial-filing dates and FMP daily prices. This is a dated response proxy, not isolated earnings causation or an assertion that the financial filing was the first public news. FY2024 annual filing occurred January 30, 2025; an earlier release may already have informed prices. Current quarter has no completed next session.

Eight completed next-session price responses · Percent change in daily close after each financial filing; unrelated news can contribute. The current ninth quarter remains unavailable at cutoff.

Next-session change

Show the data

Period	Next-session change
24 Q3	−2.283
24 Q4	2.574
25 Q1	−14.815
25 Q2	1.351
25 Q3	0.815
25 Q4	−8.23
26 Q1	−1.606
26 Q2	12.0

The print

Operating leverage is real; the headline net-income multiple is misleading.

Revenue reaches C$198.818 million, rising 32.8% year on year and 10.9% sequentially. Gross profit grows to C$52.746 million while the gross margin remains approximately 26.5%, rather than undergoing a dramatic percentage expansion. The company is earning more gross-profit dollars on a larger revenue base. Total operating expenses grow more slowly than revenue, allowing operating income to reach C$8.710 million. This is a meaningful result even after removing the downstream fair-value gains from the conversation. It should neither be dismissed as entirely accounting-driven nor confused with freely distributable shareholder cash.

The result also has to be judged against what investors already knew. On August 4 management had guided to C$195–200 million revenue, C$51–53.5 million gross profit and C$15.2–16.5 million adjusted EBITDA. The final numbers land within all three ranges. Calling September’s final print a wholly unexpected operating explosion would ignore that preannouncement. The company’s August release cited earlier Fact Set estimates in Canadian dollars, which are a useful dated reference. FMP now reports a non-null actual, confirming that the calendar entry has populated, but its converted earnings fields do not match the financial statements’ IFRS Canadian-dollar EPS basis. We do not turn those fields into an unsupported EPS beat headline.

Measure, CAD M	Q3 FY2026	Q3 FY2025	Q2 FY2026
Revenue	198.818	149.69	179.296
Gross profit	52.746	40.091	48.391
Operating income	8.71	3.739	6.097
Adjusted EBITDA	16.232	10.643	13.916
Net income	12.748	0.832	0.024
Company FCF	7.017	7.682	1.482
Basic IFRS EPS, CAD	0.13	0.01	0
Primary financial statements and MD&A; EPS is attributable income per weighted share, not consolidated net income divided by current shares.

Nine-quarter revenue and gross profit · CAD millions. Q4 calculated from annual minus nine-month financial statements.

RevenueGross profit

Show the data

Period	Revenue	Gross profit
24 Q3	131.685	35.454
24 Q4	138.295	35.755
25 Q1	142.461	35.44
25 Q2	137.804	35.471
25 Q3	149.69	40.091
25 Q4	164.031	42.528
26 Q1	178.329	44.409
26 Q2	179.296	48.391
26 Q3	198.818	52.746

August 4 preliminary range, CAD M	Low	Actual	High
Revenue	195	198.818	200
Gross profit	51	52.746	53.5
Adjusted EBITDA	15.2	16.232	16.5
Primary company guidance; final values inside each interval.

Segments and operating engine

Consolidation is not the same as ownership.

The bricks-and-mortar segment generates C$160.589 million revenue, up 7.3% year on year. Its name can mislead: the current segment includes international and United States subsidiaries as well as Canadian physical stores. It is not a clean same-store-sales measure or a Canada-only series. Management attributes much of the growth to additional stores, so higher total sales do not establish stronger productivity in the average existing store. The quarter-end network increases to 229 locations from 203 a year earlier, and the subsequent opening announcements bring the release-date count to 232. The longer-run goal of more than 350 Canadian locations is an aspiration, not a dated earnings forecast.

Remexian supplies C$38.229 million of medical-distribution revenue and C$4.414 million adjusted EBITDA this quarter. It accounts for approximately 77.8% of the consolidated year-on-year revenue increase. High Tide owns 51% of this subsidiary but consolidates 100% of its financial results because it controls the business. The 49% outside ownership is therefore a real economic claim. Our valuation applies the ownership percentage to segment earnings instead of adding all the German EBITDA to the parent’s valuation and pretending minority interests disappear. Segment gross margin reaches about 26%, and the quarter shows improved profitability, but the nine-month medical operating result remains slightly negative. That contrast makes persistence more important than annualizing one strong quarter without a sensitivity test.

Segment revenue: acquired Germany changes the mix · CAD millions; current MD&A comparative presentation, not organic same-store growth.

Bricks segmentMedical distribution

Show the data

Period	Bricks segment	Medical distribution
24 Q3	131.685	0
24 Q4	138.295	0.0
25 Q1	142.461	0.0
25 Q2	137.804	0.0
25 Q3	149.69	0.0
25 Q4	154.221	9.81
26 Q1	153.35	24.979
26 Q2	147.657	31.639
26 Q3	160.589	38.229

Segment adjusted EBITDA · CAD millions; medical business acquired September 2025. Adjusted EBITDA is a company non-IFRS measure.

Bricks segmentMedical distribution

Show the data

Period	Bricks segment	Medical distribution
24 Q3	9.614	0
24 Q4	8.245	0.0
25 Q1	7.089	0.0
25 Q2	8.062	0.0
25 Q3	10.643	0.0
25 Q4	12.432	−0.018
26 Q1	11.722	−0.265
26 Q2	10.727	3.189
26 Q3	11.818	4.414

The Canadian store base expands · Quarter-end location count; release-date 232 is a different date.

Stores

Show the data

Period	Stores
24 Q3	180
24 Q4	186.0
25 Q1	189.0
25 Q2	195.0
25 Q3	203.0
25 Q4	211.0
26 Q1	218.0
26 Q2	221.0
26 Q3	229.0

Q3 operating evidence	Reported fact	How to interpret
Cabana Club	Above 2.73 M members;27% YoY	Registered membership does not equal paying active subscribers
ELITE paid tier	Above 186 k;62% YoY	Helpful recurring economics, but contribution not separately quantified
White-label products	48 SKUs;approximately 1.9% of bricks cannabis sales	Small starting base; no unsupported mature margin forecast
Remexian shipments	More than 10 tonnes in Q3	Volume must be evaluated with price, gross profit and collections
Germany ownership	51%	Value only economic stake unless funding a buyout separately

The profit bridge

A large fair-value benefit sits below the operating result.

Start with operating income, not the rounded earnings-per-share headline. C$8.710 million operating income is reduced by C$5.578 million finance and other costs and C$0.979 million foreign-exchange loss. It is then increased by C$11.787 million from remeasurement of derivative liabilities and reduced by C$1.285 million from the long-term contract asset. The resulting C$12.655 million pretax income is lifted slightly by a net tax recovery, producing C$12.748 million consolidated net income. The net derivative/contract benefit equals 82.4% of that final income. It is a change in estimated liability and asset values, not a matching cash inflow from customers.

The company’s adjusted net income removes those two fair-value changes and is C$2.246 million. That measure is consolidated and should not be advertised as income wholly belonging to Nasdaq shareholders. Reported non-controlling interests receive C$1.457 million of quarterly net income, including C$1.310 million attributed to Remexian’s outside owners. Attribution of each normalization would require care; simply subtracting every minority amount from an adjusted group number is not a company-reported adjusted-EPS calculation. Our cash/segment valuation avoids claiming one.

The prior year illustrates why marks deserve separate treatment. FY2025 includes a C$23.564 million impairment and a large derivative remeasurement expense. Those depressed that year’s net result, whereas this quarter’s derivative benefit lifts it. Neither direction tells you how much a store or a distributor can sustainably earn. The correct response is to preserve the IFRS bridge, examine recurring operations and cash, and treat continuing control weaknesses as a reason for a wider risk range.

Q3 bridge from operating profit to net income · CAD millions; signed contributions from current interim financial statements.

Show the data

Bridge item	CAD M
Operating	8.71
Finance	−5.578
FX	−0.979
Derivative	11.787
Contract	−1.285
Tax	0.093
Net	12.748

Operating versus reported net income · CAD millions; Q4 is computed, with signs checked against annual totals.

Operating incomeNet income

Show the data

Period	Operating income	Net income
24 Q3	3.055	0.825
24 Q4	−2.831	−4.802
25 Q1	0.067	−2.689
25 Q2	0.932	−2.836
25 Q3	3.739	0.832
25 Q4	−19.186	−46.711
26 Q1	2.371	−0.352
26 Q2	6.097	0.024
26 Q3	8.71	12.748

Who receives reported Q3 profit? · CAD millions. These reported allocations are not an adjusted-earnings allocation.

Show the data

Measure	Value
Parent owners	11.291
Non-controlling owners	1.457

Earnings quality

Positive cash needs a definition and a collection check.

✔ CleanSBC / revenue

0.44%

C$0.878 M divided by C$198.818 M; still an economic expense.

▲ WatchIFRS to adjusted gap

C$10.50M

Net mark benefit removed in company adjusted net income.

✖ FlagBelow-the-line items

C$11.79 M gain

Derivative mark dominates reported net earnings.

▲ WatchMinority allocation

11.43%

Reported NCI share of quarterly group net income;51% ownership model retained.

▲ WatchCash conversion

C$5.61M

Q3 OCF less all PPE/intangible capex and leases; before NCI.

▲ WatchReceivable days

4.7 days

Period-end net receivables×91/revenue; factoring makes this look lower.

▲ WatchInventory days

42.0 days

Period-end inventory×91/cost of sales, not average-balance turnover.

▲ WatchEffective tax

−0.73%

Net quarterly tax recovery; unsuitable normalized tax rate.

✔ CleanGuidance record

Within August range

Revenue, gross profit and adjusted EBITDA met preliminary ranges.

Working capital deserves more attention as Germany grows. Trade accounts receivable before factoring and allowance is C$30.922 million, while the balance-sheet receivable figure is only C$10.199 million. The bridge includes C$19.131 million of receivables sold through nonrecourse factoring and C$1.592 million allowance. Eligible receivables are derecognized when the financing company buys them and cash is received; the company states that it retains no ongoing credit risk beyond customary representations. This is different from simply borrowing against an unchanged receivable balance, and it should not be relabeled as ordinary debt without evidence.

Nevertheless, factoring changes the apparent collection cycle and incurs finance costs. A short receivable-days ratio using the net balance is therefore not proof that all customers pay unusually quickly. Nor is the change in the outstanding factoring offset automatically equal to incremental quarterly operating cash flow: purchases, collections and currency movements occur throughout the period. We flag the mechanism, show both balances and ask for cash-flow disclosure rather than inventing a subtraction.

Control quality is a separate concern. Management concludes that disclosure controls are ineffective, with continuing weaknesses in IT access/change management and the preparation and review of complex or nonroutine financial information. Remediation is underway but was not fully effective at July 31. That is not an allegation that the current accounts are false. It means high-complexity mark-to-model and acquisition entries deserve greater uncertainty and closer reconciliation. We do not calculate Beneish or Altman scores from mismatched definitions merely to fill a dashboard.

Non-IFRS bridge components in Q3 · CAD millions. Selected components; complete nine-quarter reconciliation retained in the dataset.

Show the data

Measure	Value
SBC add-back	0.878
Transaction costs	2.047
FX loss	0.979
Contract mark	1.285
Derivative gain removed	−11.787

Working-capital days are proxies, not collection promises · Computed using period-end balances and 91 days; acquisition, factoring and seasonality limit comparability.

Net receivable daysInventory days

Show the data

Period	Net receivable days	Inventory days
24 Q3	1.822	27.488
24 Q4	2.177	26.036
25 Q1	2.212	25.847
25 Q2	1.817	25.1
25 Q3	2.159	25.954
25 Q4	3.115	50.846
26 Q1	4.426	45.527
26 Q2	3.919	50.146
26 Q3	4.668	42.021

Annual operating cash and reinvestment · CAD millions; all-capex figure includes PPE, intangibles and lease payments. No double subtraction of financing interest.

Operating cashAll capex plus lease payments

Show the data

Period	Operating cash	All capex plus lease payments
2023	20.661	17.146
2024	35.546	20.625
2025	23.866	20.3

Cash and balance sheet

Separate the accounting balance from the obligations equity must fund.

The company-defined C$7.017 million quarterly free cash flow already deducts C$0.492 million sustaining capital expenditure and C$2.582 million lease payments from C$10.091 million operating cash. Subtracting rent again from that FCF would be wrong. But expansion capital is also a real use of funds. Q3 purchases of PPE and intangibles total C$1.898 million, calculated from nine-month totals less the six-month filing. Replacing sustaining capital with those actual purchases leaves C$5.611 million. This is our transparent all-capex, after-lease cash proxy, not a replacement name for the company’s measure. It remains consolidated, before minority distributions and acquisition spending.

The year-to-date version is C$6.631 million, so the latest quarter supplies most of the nine-month total. Annualizing it would hide that timing. The company’s trailing FCF is C$12.761 million, compared with a quarter that on its own looks much stronger. Cash conversion has improved sequentially but is not a demonstrated C$25–30 million recurring owner stream. Inventory, prepaid balances, supplier terms and receivable sales can move the result materially.

At July 31 unrestricted cash is C$38.019 million; C$9.103 million is restricted and is excluded from our cash offset. Debt carrying amounts total C$61.283 million across loans, notes, secured debentures and convertible debt. The face-obligation convention used for valuation is C$77.079 million, including the C$30 million convertible face amount and C$15 million secured debentures. The difference reflects discounts and accounting measurement, not extra bank cash. August’s BMO facilities and repayment of connect First are subsequent events. We acknowledge them but do not manufacture a fully drawn pro-forma debt balance or count undrawn credit as cash.

Q3 cash bridge	CAD M	Treatment
Operating cash	10.091	Reported
Sustaining capex	−0.492	Company FCF definition
Lease payments	−2.582	Already in company FCF
Company FCF	7.017	Reported non-IFRS
Replace sustaining with total capex	−1.406	Computed additional spending
All-capex cash proxy	5.611	Before NCI and acquisitions
YTD all-capex proxy	6.631	Timing caveat

What the capital structure contains · CAD millions; categories are different measurement bases and must not be indiscriminately summed.

Show the data

Measure	Value
Unrestricted cash	38.019
Restricted cash	9.103
Carrying financial debt	61.283
Face financial debt	77.079
Lease liabilities	62.188
Derivative liabilities	52.521

Combined cash balances by quarter · CAD millions. Combined reported balances across changing classifications; no zero restricted cash is inferred for historical periods without a separate split.

Cash including restricted

Show the data

Period	Cash including restricted
24Q3	35.254
24Q4	47.267
25Q1	33.341
25Q2	34.692
25Q3	63.809
25Q4	47.883
26Q1	46.374
26Q2	36.521
26Q3	47.122

Capital treatment	Base model convention	Reason
Loans and vendor notes	Face/principal obligations where disclosed	Accounting discounts do not eliminate settlement requirements
Convertible financing	Debt retained; no conversion credited	Avoid treating debt as both forgiven and share-free
Lease liabilities	Excluded from EV; rent expensed in model	Consistent operating-rent valuation convention
Remexian put obligation	Excluded while valuing only retained 51%	An exercise requires separate funding and ownership-model refresh
Detachable warrants	No immediate cash debt deduction	Exercise/dilution remains a separate sensitivity
Shares	88.897395 M current common shares	EPS weighted basic/diluted averages serve a different purpose

Valuation

Three explicit routes; an optimistic cash assumption still leaves little discount.

All operating model inputs are Canadian dollars. Convert only the final per-share result into Nasdaq dollars using the savedUSD0.71948 perCAD reference. The base quote implies approximately C$324.96 million equity value; adding C$39.06 million net face debt produces C$364.02 million enterprise value under our rent-expensed,51%-owned convention. At a nine-times multiple, that enterprise value requires about C$40.45 million of owned annual cash operating profit after rent and SBC, close to our C$42 million assumption. The current price therefore already asks for much of the operational improvement we are willing to underwrite.

The first route begins with owned adjusted EBITDA: four times quarterly consolidated C$16.232 million, less 49% of Remexian’s C$4.414 million quarterly contribution, gives C$56.277 million. We then allow for rent, SBC and normalization to arrive at C$42 million annual profit before financing and tax. This is an analyst assumption, not a reported metric. Nine times that amount, minus net face debt, supportsUSD2.74 per share.

The second route values the businesses separately. Bricks quarterly EBITDA annualizes to C$47.272 million; deduct modeled C$10.6 million cash rent and C$2.844 million SBC, then apply 9 times. Medical earnings are 51% of four times C$4.414 million, less C$0.4 million modeled recurring leakage, valued at 8 times. Subtract the same net face debt once. The result isUSD2.71. This is not wholly independent of the first route: both rely on operating earnings, so the cash-flow route is an essential countercheck.

The third route discounts equity cash flows after interest, tax, total reinvestment, rent and minority economics. Starting from an assumed C$24 million normalized base, cash flows grow 10% for five years; a 14% cost of equity and 3% terminal growth implyUSD2.39. Because these are equity cash flows, net debt is not subtracted again. The C$24 million starting assumption is already above demonstrated trailing company FCF; it is a requirement for improvement, not a fact about today’s cash engine.

Owned operating-profit multiple

(C$42 M×9−C$39.06 M)÷88.897 M×0.71948 = USD2.743.

Ownership-adjusted sum of parts

(C$33.828 M bricks×9+C$8.605 M medical×8−C$39.06 M)÷88.897 M×0.71948 = USD2.705.

Equity cash-flow DCF

Five modeled cash flows C$26.40/29.04/31.94/35.14/38.65 M discounted at 14%, terminalgrowth 3%; per-share conversion = USD2.395.

Routes and current price · USD per common share, not millions. Equal-route average rounded to one decimal.

Show the data

Measure	Value
multiple	2.7432
sotp	2.705
equity_cashflow_dcf	2.395
Base fair value	2.6
Price	2.63

Sensitivity to owned profit and valuation multiple · USD per share; fixed C$39.06 M net face debt,88.897 M shares,USD0.71948/CAD. Profit is after cash rent and SBC, before financing/tax.

Show the data

Profit	6×	8×	9×	10×	12×
30	1.14	1.63	1.87	2.11	2.6
36	1.43	2.01	2.31	2.6	3.18
42	1.72	2.4	2.74	3.08	3.76
48	2.01	2.79	3.18	3.57	4.35
56	2.4	3.31	3.76	4.22	5.12

The equal-weight mean of the three routes isUSD2.614, rounded to USD2.60. A10% larger share denominator with unchanged business value would reduce that base to aboutUSD2.36; this is an illustrative dilution stress, not a forecast of a specific issuance. No US adult-use entry, remaining 49% Remexian purchase, or unannounced deal is included as free upside. Such events need separate financing and regulatory analysis.

Very High uncertainty calls for a meaningful discount. Our watch threshold is 30% belowUSD2.60, orUSD1.82, provided the operating thesis and financing position remain intact. AtUSD2.63, the lack of that cushion supports HOLD rather than a confident purchase recommendation. The bull case can work, but it needs both higher owned earnings and investor willingness to pay a stronger multiple; the bear case has two moving parts in the other direction.

Wall Street context

Separate a current rating from a stale target and a preannouncement benchmark.

The canonical Street pull reports a Buy-oriented rating summary, but freshness must be evaluated at the underlying observation level. FMP’s dated history includes a Canaccord Genuity Buy maintenance on March 19, 2026 and a Roth Capital Buy maintenance on June 18, 2025. The target-news endpoint returned only a Cantor Fitzgerald observation from February 2023 at USD2.70. It is not a new target following this quarter, even if a summary endpoint reproduces the same number. A precise target with an old timestamp is less useful than a clearly qualified current assessment.

There is also a currency problem in the annual analyst-estimates feed: it supplies numeric revenue and earnings fields without identifying the currency in the returned records. We preserve those raw values and analyst counts for audit, but do not blend them with the USD-converted earnings-calendar fields or claim an apples-to-apples forecast comparison. Instead, the company’s August 4 release explicitly identifies its Fact Set comparison in C$millions as of August 3. At that time revenue consensus was C$183.4 million, gross profit C$49.3 million and adjustedEBITDA C$14.0 million. Final results exceed those dated estimates, but the market had management’s higher guidance for several weeks.

Our HOLD disagrees with the optimistic rating direction because we apply a higher cash and ownership hurdle, not because we possess a fresher analyst target than the feed actually provides. A post-call change in estimates would be useful new evidence. It would not automatically override the required profit-to-cash reconciliation or justify counting consolidated medical earnings as wholly owned.

Firm/source	Date	Verified observation	Freshness
Canaccord Genuity	Mar 19 2026	Buy maintained	Before Q3; no current target verified
Roth Capital	Jun 18 2025	Buy maintained	Stale rating observation
Cantor Fitzgerald target news	Feb 27 2023	USD2.70 target	Historical; not current consensus
Charged Alpha	Sep 15 2026	HOLD;USD2.60 model value	This packet, source cutoff before call

Dated operating benchmark: final versus August Fact Set · CAD millions; company-disclosed Fact Set snapshot. This is not the consensus immediately before September 14.

Show the data

Measure	Value
Revenue:Aug 3 consensus	183.4
Revenue:final	198.818

Preannouncement context in profit metrics · CAD millions; both estimates had been superseded by management’s August 4 ranges before the final release.

Aug 3 Fact SetFinal Q3

Show the data

Period	Aug 3 Fact Set	Final Q3
Gross profit	49.3	52.746
Adjusted EBITDA	14	16.232

Management scorecard

Judge delivery, capital discipline and disclosure quality separately.

Management earns credit for hitting the August preliminary financial ranges and for bringing the German business to materially better quarterly profitability. The store rollout also continues, and the paid ELITE tier is growing. These are observable operating achievements. They do not require endorsing every long-term ambition or using promotional market-share language as independently verified industry data. The company itself notes limitations in the available German industry data, so shipment momentum and claimed market share should remain distinct.

Capital allocation is more mixed. Buying control of a promising medical distributor can create a second growth engine, but it also introduces minority claims, vendor financing, option liabilities and accounting complexity. The Northern Helm transaction and Canadian expansion add further reinvestment needs. The BMO facility is a useful financing development, yet undrawn capacity is not free cash, and refinancing does not by itself improve the underlying return earned on assets. We would prefer future disclosures that connect store cohorts and medical volumes to after-rent returns and cash actually available to parent owners.

Governance has ordinary protections and genuine weaknesses. Common shares carry one vote each, with no ADRconversion ratio. The annual information form reports founder Raj Grover’s approximately 7.88% ownership at that document’s date, not at today’s date. It also discloses premises leased from a Grover-controlled company. The completed August shareholder vote was uncontested, and the rights-plan announcement says it was not adopted in response to a known anticipated takeover. Those facts clear the corporate-event screen but do not erase the disclosed financial-control weaknesses.

Area	Assessment	Evidence / question
Guidance delivery	Positive	Final revenue, gross profit and EBITDA within preliminary ranges
Canada growth	Positive but incomplete	More stores and paid members; need cohort returns
Germany integration	Improving	C$4.414 Mquarter EBITDA; nine-month operating loss still C$0.154 M
Cash discipline	Mixed	Positive company FCF, lower after full reinvestment; factoring expands
Controls	Weak	IT and nonroutine transaction weaknesses remain ineffective
Capital structure	Complex	Minorityput, warrants, convertible debt and vendor obligations
Related parties	Monitor	AIF premises lease C$386 kannual payments, stated market rates

What is parent-owned cash flow after every recurring capital and financing cost, separately from consolidated FCF?
How much of the medical business’s quarterly cash generation depends on factoring, and what are the all-in fees?
What are mature-store and new-store returns after rent, payroll and all opening costs?
Which precise controls have passed operating-effectiveness testing, and by what date will the remaining weaknesses be remediated?
How would buying the remaining Remexian stake be funded without assuming both free ownership and no dilution?

Risks and counterarguments

The upside case is credible; it still has financing and execution conditions.

The strongest bull argument is that High Tide has finally assembled two businesses capable of scaling together. Canada supplies a large loyalty-led retail network, while Germany offers a growing medical-distribution market and supply relationships. The quarter’s operating leverage suggests the extra gross-profit dollars need not all disappear into overhead. With better rent-adjusted returns and stable working capital, owner cash flow could rise much faster than sales. A valuation near today’s level would then understate future earning power.

The strongest bear argument is that acquisitions and accounting measures make that earning power look further advanced than the cash record supports. Remexian is only 51% owned, its growth needs working capital, and the reported net-income gain largely reflects marks. Canadian store growth is not the same as comparable-store productivity. A weak regulatory outcome, lower wholesale pricing, or difficulty financing another purchase could reduce both cash generation and the multiple the market is willing to pay for it.

We land between these cases. Operating progress is sufficient to avoid treating the company as a purely speculative promise, but valuation lacks the discount required for the uncertainty. The issue is not whether a shareholder can imagine a much bigger network. It is whether the current price leaves enough room for the amount of recurring owner cash that survives growth spending, contractual obligations and adverse changes in regulation. Our base case does not assign value to a hypothetical US adult-use entry; management’s exploration of that possibility is not an established operating permission or a funded plan.

Ranked risk	Likelihood	Impact	Monitoring evidence
1.German regulation/access	Medium	High	Medical demand, prescribing/distribution rules, shipment and price trends
2.Cash conversion/reinvestment	High	High	Full capex, factoring, inventory, parent distributions
3.Accounting/control weaknesses	High current exposure	High	Remediation evidence; complex transaction reconciliations
4.Financing/dilution	Medium	High	Debt draws, rights exercise, share issuance and covenant disclosures
5.Domestic competition	High	Medium	Existing-store productivity and paid membership economics
6.Acquisition/ownership terms	Medium	High	Remexianput funding and acquisition-return disclosures
7.Foreign exchange	Medium	Medium	CAD operating value converted into USD share price
Likelihood and impact are analyst judgments, not probabilities derived from a statistical model.

Catalysts and dated checks

The next evidence should resolve cash persistence, not merely another record headline.

The imminent conference call may clarify cash conversion, German economics and the status of the new financing facilities. Because it had not occurred at our cutoff, this packet neither quotes management answers nor assumes a forecast change. If new material information arrives, it should be added through a documented source review rather than retroactively represented as known when the episode was prepared.

By calendar year-end, the opening cadence can be tested against the goal of at least 20 additional Canna Cabana locations. Hitting that count is only the first part of the test. Returns should remain attractive after opening costs and rent, and growth should not depend on unexpectedly dilutive funding. The company’s more-than 350 store long-term ambition has no firm completion date here and is excluded from near-term valuation arithmetic.

The next annual result will provide a fuller cash-flow and balance-sheet picture, including the effect of the August BMO closing and connect First repayment. It is also the natural point to revisit controls, related-party arrangements and acquisition obligations. Exact publication dates have not been announced in the reviewed sources, so January 31, 2027 is our research-review deadline, not a fabricated earnings date. A change in regulation or financing can require an earlier review. Conversely, a price rally with no improvement in owner cash would reduce expected return rather than prove the bull case.

Date / window	Event	What would change the thesis
Sep 15 2026,11:30 a.m.ET	Scheduled results call	Source-backed clarification of cash, medical margins and financing
Through Dec 31 2026	Store openings and operating updates	At least 20 calendar openings with returns and funding intact
Next FY2026 report; date unannounced	Full-year financial statements	Persistent full-capex cash and post-refinancing debt bridge
By Jan 31 2027	Charged Alpha research review deadline	Grade all signposts; refresh valuation and share count
As announced	Regulatory or acquisition developments	Re-underwrite the affected operation and funding needs

Appendix and methods

Primary-source financial tables, computed history and explicit limitations.

The dataset behind this packet retains the full income statements, balance sheets, cash-flow statements, segment notes, share-count notes and non-IFRS reconciliation tables for nine quarters, together with three fiscal years of cash-flow data. Annual financials and interim comparatives provide cross-checks. Fourth-quarter income-statement values are computed as annual minus nine-month figures; EPS is not calculated by subtracting annual and year-to-date EPS, because the weighted share denominators differ. Signed expenses, including impairments and tax recoveries, remain signed throughout the model.

Historical segment presentations changed when Germany entered the group. The current comparative series is used where management provides it; it is not claimed to be an organic or constant-currency reconstruction. The working-capital days charts use quarter-end balances and 91 days rather than unavailable monthly averages. Company-defined FCF deducts sustaining capital and leases; our alternative cash proxy substitutes totalPPE and intangible purchases. Neither is automatically cash distributable to parent common shareholders. The currency convention is deliberately explicit: financial amountsCAD millions, original tablesCAD thousands, and final Nasdaq valuesUSD per common share.

The previous channel episode coversQ2 FY2026 under the title “The Tiny Cannabis Name That Just Turned Its First Real Profit.” It is preserved as a prior-quarter record. The current research examines the new quarter’s operating scale, accounting bridge and owner cash. No prior published signpost ledger was available, so we do not invent a retrospective score or claim to have upgraded an earlier documented fair value. The seven dated checks in this packet establish a concrete baseline for the next review.

Quarter	Revenue CAD M	Operating income	Net income	Adjusted EBITDA	Company FCF	Stores
2024 Q3	131.685	3.055	0.825	9.614	3.092	180
2024 Q4	138.295	−2.831	−4.802	8.245	5.908	186.0
2025 Q1	142.461	0.067	−2.689	7.089	−1.9	189.0
2025 Q2	137.804	0.932	−2.836	8.062	4.896	195.0
2025 Q3	149.69	3.739	0.832	10.643	7.682	203.0
2025 Q4	164.031	−19.186	−46.711	12.414	1.323	211.0
2026 Q1	178.329	2.371	−0.352	11.457	2.939	218.0
2026 Q2	179.296	6.097	0.024	13.916	1.482	221.0
2026 Q3	198.818	8.71	12.748	16.232	7.017	229.0
Computed Q4 values reconciled against annual totals; source statement rows retained.

FY	OCF CAD M	PPE capex	Intangibles	Lease payments	All-capex cash after leases	SBC	Employees at following AIF
2023	20.661	5.786	0.295	11.065	3.515	5.034	1550
2024	35.546	8.217	0.703	11.705	14.921	2.975	1750
2025	23.866	10.084	0.209	10.007	3.566	3.917	1832
Employees are approximate January AIF-date counts, not fiscal-year-end totals. No common cash dividends or common repurchases identified.

Primary source	Link
Q3 release	Q3 release
Q3 interim financials	Q3 interim financials
Q3 MD&A	Q3 MD&A
FY2025 annual financials	FY2025 annual financials
FY2025 annual information form	FY2025 annual information form
FY2024 annual financials	FY2024 annual financials
FY2023 annual financials	FY2023 annual financials
August preliminary guidance	August preliminary guidance
Primary filings and dated market observations support the financial tables and model; FMP market data was retrieved September 15.

Terminology: IFRS means International Financial Reporting Standards. Adjusted EBITDA is the issuer’s earnings measure before selected financing, tax, depreciation and other adjustments, and is not standardized across companies. NCI means non-controlling interests, the outside owners of consolidated subsidiaries. Factoring means selling qualifying receivables to obtain cash before customer collection, under the disclosed nonrecourse arrangement. Face debt means contractual principal rather than its discounted accounting balance. FCFE means cash flow available to equity after financing costs; consequently it is valued without subtracting debt a second time.

The research is based on the actual SEC financial statements and results release. Current submissions were screened through September 14, 2026. Historical Form 40-F/A and 6-K/Aclusters were examined: explanatory notes describe administrative incorporation, date/label/signature corrections and clawback-policy additions rather than restated financial results. The company’s current disclosed material weaknesses remain a risk separately from those administrative amendments. The tables above identify calculated values and valuation assumptions so readers can inspect the economic reasoning.